Florida Digestive hosted a precancer detection event at the Gastroenterology Associates of Sarasota (Fla.) under the direction of Sarasota Memorial Hospital’s chief of gastroenterology, Scott Corbett, MD.
EsoGuard is the first and only commercial diagnostic test capable of detecting esophageal precancer in at-risk individuals, according to a June 5 press release.
At the testing event, Lucid personnel will collect cheek swab samples from patients that will be sent to a molecular diagnostic laboratory in Lake Forest, Calif. Patients with positive EdoGuard test results will be recommended for monitoring and treatment.
Over 80 percent of patients with esophageal cancer die within five years of diagnosis, making it the second most lethal cancer in the U.S.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
